New combo therapy shows promise for tough lung cancer
NCT ID NCT02143466
First seen Oct 31, 2025 · Last updated May 20, 2026 · Updated 23 times
Summary
This early-stage study tests the safety and best dose of a drug called AZD9291 (osimertinib) combined with either AZD6094 or selumetinib in people with advanced EGFR-mutant lung cancer that has stopped responding to previous treatments. About 344 adults with this specific type of lung cancer will take part. The goal is to find a safe combination that might control the cancer better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Research Site
Atlanta, Georgia, 30329, United States
-
Research Site
Boston, Massachusetts, 02114, United States
-
Research Site
Boston, Massachusetts, 02215, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Philadelphia, Pennsylvania, 19111, United States
-
Research Site
Nashville, Tennessee, 37232, United States
-
Research Site
Calgary, Alberta, T2N 4N2, Canada
-
Research Site
Edmonton, Alberta, T6G 1Z2, Canada
-
Research Site
Chūōku, 104-0045, Japan
-
Research Site
Habikino-shi, 583-8588, Japan
-
Research Site
Hirakata-shi, 573-1191, Japan
-
Research Site
Kashiwa, 227-8577, Japan
-
Research Site
Nagoya, 460-0001, Japan
-
Research Site
Nagoya, 464-8681, Japan
-
Research Site
Gdansk, 80-952, Poland
-
Research Site
Krakow, 31-202, Poland
-
Research Site
Olsztyn, 10-357, Poland
-
Research Site
Poznan, 60-569, Poland
-
Research Site
Warsaw, 02-781, Poland
-
Research Site
Chelyabinsk, 454087, Russia
-
Research Site
Krasnoyarsk, 660133, Russia
-
Research Site
Moscow, 115478, Russia
-
Research Site
Omsk, 644013, Russia
-
Research Site
Saint Petersburg, 195271, Russia
-
Research Site
Saint Petersburg, 197002, Russia
-
Research Site
Saint Petersburg, 197022, Russia
-
Research Site
Saint Petersburg, 197342, Russia
-
Research Site
Saint Petersburg, 197758, Russia
-
Research Site
Cheongju-si, 28644, South Korea
-
Research Site
Goyang-si, 10408, South Korea
-
Research Site
Seongnam-si, 13620, South Korea
-
Research Site
Seoul, 03722, South Korea
-
Research Site
Seoul, 05505, South Korea
-
Research Site
Seoul, 6351, South Korea
-
Research Site
Kaohsiung City, 82445, Taiwan
-
Research Site
Kaohsiung City, 83301, Taiwan
-
Research Site
Tainan, 704, Taiwan
-
Research Site
Taipei, 10002, Taiwan
-
Research Site
Taipei, 112, Taiwan
-
Research Site
Taipei, 235, Taiwan
-
Research Site
Kyiv, 03022, Ukraine
-
Research Site
Vinnytsia, 21029, Ukraine
Conditions
Explore the condition pages connected to this study.